Full history for every metric is available with a Kvantra account
Carbiotix AB (CRBX.ST)
Key financial summary
Financials in SEK| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | SEK m | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Operating profit | SEK m | -16 | -14 | |||||
| Net profit | SEK m | -5 | -6 | -10 | -12 | -13 | -16 | -14 |
| EPS reported | SEK | -4.29 | -3.34 | |||||
| Operating cashflow per share | SEK | -5.18 | -1.39 | |||||
| Capex per share | SEK | 0.50 | 0.20 | |||||
| FCF per share | SEK | -5.68 | -1.59 | |||||
| Free cash flow | SEK m | -21 | -16 | |||||
| Net debt | SEK m | -1 | -1 | |||||
| Book value equity | SEK m | 23 | 23 | |||||
| Book value per share | SEK | 5.99 | 4.66 | |||||
| Number of shares | m | 3.76 | 4.95 | |||||
| DPS (TTM paid) | SEK | 0.00 | 0.00 |
Financial summary
Financials in SEK| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.95 | 1.42 | |||||
| P/S LTM | x | 44.75 | 36.97 | |||||
| P/FCF LTM | x | -2.05 | -2.06 | |||||
| EV/EBITDA LTM | x | -2.69 | -2.25 | |||||
| EV/Sales LTM | x | 43.46 | 36.29 | |||||
| Earnings Yield LTM | % | -36.82% | -21.32% | |||||
| FCF Yield | % | -48.77% | -48.53% | |||||
| Quality | ||||||||
| ROE | % | -71.66% | -30.00% | |||||
| ROIC | % | -71.05% | -30.11% | |||||
| Operating margin | % | -1633.9% | -897.04% | |||||
| Gross margin | % | 177.84% | 216.42% | |||||
| FCF/Sales | % | -2182.4% | -1017.5% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -33.20% | -24.08% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 0.08 | 0.09 | |||||
| EBIT/Net interest | x | -115.85 | -92,658.04 | |||||
| Net debt/market cap | % | -2.88% | -1.85% | |||||
| Net debt/Equity | x | -0.06 | -0.03 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Carbiotix AB is a therapeutics company currently in the pre-clinical development stage. It specializes in creating products and medicines intended to stimulate beneficial bacteria in the gut, with the aim of addressing metabolic and chronic illnesses. The company was established in 2014 and is headquartered in Lund, Sweden.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Carbiotix AB (CRBX.ST)
Carbiotix AB is a therapeutics company currently in the pre-clinical development stage. It specializes in creating products and medicines intended to stimulate beneficial bacteria in the gut, with the aim of addressing metabolic and chronic illnesses. The company was established in 2014 and is headquartered in Lund, Sweden.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free